EFFECT OF AN OPTIMIZED TREATMENT REGIMEN ON THE DYNAMICS OF FETUIN-A, TLR4 AND INFLAMMATION BIOMARKERS IN RHEUMATOID ARTHRITIS
Keywords:
rheumatoid arthritis, Fetuin-A, TLR4, systemic inflammation, ademetionine, EULAR/ACR response, optimized regimenAbstract
This article discusses the influence of an optimized complex treatment regimen on serum levels of Fetuin-A, Toll-like receptor 4 (TLR4) and systemic inflammation biomarkers (IL-1β, IL-6, TNF-α, anti-CCP) in patients with rheumatoid arthritis (RA). The study was conducted in 2024-2026 at the Rheumatology Department of the National Medical Center. A total of 140 patients with confirmed RA based on EULAR/ACR-2010 criteria and 36 practically healthy individuals were enrolled. The patients were divided into four subgroups according to the clinical form of the disease and type of therapy. The results of the 12-week follow-up demonstrated that the optimized complex regimen restores Fetuin-A levels, reduces TLR4 expression, decreases IL-1β, IL-6, TNF-α and anti-CCP concentrations by 2.5-3.5 times compared with the conventional scheme, and improves clinical efficacy according to EULAR/ACR response criteria. The most pronounced positive response was registered in patients with the extra-articular clinical form of the disease.
References
Demetriou M., Binkert C., Sukhu B., Tenenbaum H.C., Dennis J.W. Fetuin/α2-HS glycoprotein is a transforming growth factor-β type II receptor mimic and cytokine antagonist // J. Biol. Chem. - 1996. - Vol. 271, № 22. - P. 12755-12761.
Fraenkel L., Bathon J.M., England B.R. et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis // Arthritis Care Res. (Hoboken). - 2021. - Vol. 73, № 7. - P. 924-939.
Edilova M.I., Akram A., Abdul-Sater A.A. Innate immunity drives pathogenesis of rheumatoid arthritis // Biomed. J. - 2021. - Vol. 44, № 2. - P. 172-182.
Gobejishvili L., Avila D.V., Barker D.F. et al. S-Adenosylmethionine decreases lipopolysaccharide-induced phosphodiesterase 4B2 and attenuates TNF expression // J. Pharmacol. Exp. Ther. - 2014. - Vol. 347, № 1. - P. 191-202.
Goh F.G., Midwood K.S. Intrinsic danger: activation of Toll-like receptors in rheumatoid arthritis // Rheumatology (Oxford). - 2012. - Vol. 51, № 1. - P. 7-23.
Trouw L.A., Mahler M. Closing the serological gap: promising novel biomarkers for the early diagnosis of rheumatoid arthritis // Autoimmun. Rev. - 2015. - Vol. 14, № 1. - P. 51-61.
Pal D., Dasgupta S., Kundu R. et al. Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance // Nat. Med. - 2012. - Vol. 18, № 8. - P. 1279-1285.
Roumeliotis S., Roumeliotis A., Stamou A. et al. The association of fetuin-A with cardiovascular disease in rheumatic and renal patients: an updated review // Int. J. Mol. Sci. - 2022. - Vol. 23, № 15. - P. 8093.
Huang Q.Q., Pope R.M. The role of Toll-like receptors in rheumatoid arthritis // Curr. Rheumatol. Rep. - 2009. - Vol. 11, № 5. - P. 357-364.
Sari I., Birlik M., Akkoc N. et al. Fetuin-A levels in patients with rheumatoid arthritis: relationship with disease activity, radiological damage and bone metabolism // Clin. Rheumatol. - 2020. - Vol. 39, № 2. - P. 413-421.
Olejarz W., Łacheta D., Głuszko A. et al. Fetuin-A: a novel biomarker for rheumatic diseases - a comprehensive review // Cells. - 2024. - Vol. 13, № 7. - P. 578.
McInnes I.B., Schett G. The pathogenesis of rheumatoid arthritis // N. Engl. J. Med. - 2011. - Vol. 365, № 23. - P. 2205-2219.
Sato H., Kazama J.J., Wada Y. et al. Decreased levels of circulating α2-Heremans-Schmid glycoprotein/fetuin-A in patients with rheumatoid arthritis // Intern. Med. - 2007. - Vol. 46, № 20. - P. 1685-1692.
Zhang L., Cao B., Bai C. Global, regional and national burden of rheumatoid arthritis, 1990-2021 // RMD Open. - 2025. - Vol. 11, № 1. - P. e004597.
Tekeoglu I., Harman H., Sag S. et al. Levels of serum pentraxin-3, IL-6, fetuin-A, and insulin in patients with rheumatoid arthritis // Cytokine. - 2016. - Vol. 83. - P. 171-175.
Smolen J.S., Landewé R.B.M., Bergstra S.A. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update // Ann. Rheum. Dis. - 2023. - Vol. 82, № 1. - P. 3-18.
